Metastatic dissemination of solid tumors, a leading cause of cancer-related mortality,
underscores the urgent need for enhanced insights into the molecular and cellular …

With the identification of activating mutations in BRAF across a wide variety of malignancies,
substantial effort was placed in designing safe and effective therapeutic strategies to target …

In June 2022, the FDA granted Accelerated Approval to the BRAF inhibitor dabrafenib in
combination with the MEK inhibitor trametinib for the treatment of adult and paediatric …

PURPOSE Non-V600 mutations comprise approximately 35% of all BRAF mutations in
cancer. Many of these mutations have been identified as oncogenic drivers and can be …

In-frame BRAF exon 12 deletions are increasingly identified in various tumor types. The
resultant BRAFΔβ3-αC oncoproteins usually lack five amino acids in the β3-αC helix linker …

Serine/threonine-protein kinase B-Raf (BRAF; RAF= rapidly accelerated fibrosarcoma) plays
an important role in the mitogen-activated protein kinase (MAPK) signaling cascade …

Pancreatic ductal adenocarcinoma (PDAC) presents significant challenges for targeted
clinical interventions due to prevalent KRAS mutations, rendering PDAC resistant to RAF …

The RASopathies are a group of clinically defined developmental syndromes caused by
germline variants of the RAS/mitogen‐activated protein (MAPK) cascade. The prototypic …

Pancreatic cancer represents a formidable challenge in oncology, primarily due to its
aggressive nature and limited therapeutic options. The prognosis of patients with pancreatic …

Anaplastic thyroid cancer is an extremely lethal malignancy without reliable treatment.
BRAFV600E point mutation is common in ATCs, which leads to MAPK signaling activation …